Cord Blood News Volume 6.30 | Aug 7 2014

Outcome of Aplastic Anemia in Adolescence. A Survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation
Investigators analyzed the outcome of 537 adolescents with idiopathic aplastic anemia included in the data-base of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation comparing matched family donor hematopoietic stem cell transplantation performed as first line treatment with front-line immunosuppressive therapy not followed by subsequent transplant given for failure and with hematopoietic stem cell transplantation performed after failed front-line immunosuppressive therapy. [Haematologica] Abstract | Full Article

CMV Upregulates Expression of CCR5 in Central Memory T_CM Cord Blood Mononuclear Cells which May Facilitate In Utero HIV-1 Transmission
Maternal co-opportunistic infection with primary or reactivated cytomegalovirus (CMV) or other pathogens may facilitate in utero transmission of HIV-1 by activation of cord blood mononuclear cells. Scientists examined the targets and mechanisms that affect fetal susceptibility to HIV-1 in utero. [J Infect Dis] Abstract | Full Article

Overexpression or Silencing of FOXO3a Affects Proliferation of Endothelial Progenitor Cells and Expression of Cell Cycle Regulatory Proteins
Researchers investigated the effects of changes in Forkhead box O (FOXO)3a activity on cell proliferation and cell cycle regulatory proteins in endothelial progenitor cells (EPCs). The constructed recombinant adenovirus vectors Ad-triple mutant-FOXO3a, Ad-shRNA-FOXO3a and the control Ad-GFP were transfected into EPCs derived from human umbilical cord blood. [PLoS One] Full Article

Human Diploid MRC-5 Cells Exhibit Several Critical Properties of Human Umbilical Cord-Derived Mesenchymal Stem Cells
Researchers compared MRC-5 with human umbilical cord-derived mesenchymal stem cells (MSCs), which serves as a representative of human MSCs, in expression of cell surface markers, abilities to differentiate into multiple cell lineages, inhibition of lymphocyte proliferation and promotion of regulatory T lymphocytes, and IDO1 expression in response to inflammatory cytokines, all of which are critical properties of MSCs. [Vaccine] Abstract

Outcome of Graft Failure after Allogeneic Stem Cell Transplant: Study of 89 Patients
Strategies for reversing graft failure (GF) after allogeneic stem cell transplant (SCT) depend on the options available in each situation. GF was reported in 16 Spanish institutions. Primary GF was defined as an absolute neutrophil count >0.5 × 10⁹/L not reached by day + 28 after SCT from peripheral blood or bone marrow progenitors and by day + 42 after SCT from unrelated cord blood progenitors. [Leuk Lymphoma] Abstract

Effect of Graft Sources on Allogeneic Hematopoietic Stem Cell Transplantation Outcome in Adults with Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Japanese Society of Hematopoietic Cell Transplantation Retrospective Analysis
Researchers retrospectively compared transplant outcomes for related bone marrow transplantation, related peripheral blood stem cell transplantation, unrelated bone marrow transplantation, and unrelated cord blood transplantation in 1,062 patients with chronic myeloid leukemia aged 20 years or over in Japan. [Int J Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Cesca Therapeutics and Fortis Healthcare Announce Master Collaboration Agreement
Cesca Therapeutics and Fortis Healthcare Limited announced a master collaboration agreement that extends their important existing relationship. The agreement affirms Cesca’s cellular therapy and cord blood bank at the Fortis Hospital Memorial Research Institute, renews the cord blood banking collaboration and launches the stem cell therapy services for hematological diseases across the Fortis network. [Cesca Therapeutics Inc. (GlobeNewswire)] Press Release

AMNIOX^® Medical Announces Initiation of Prospective, Randomized, Controlled Clinical Study of Chronic Wounds
Amniox Medical, Inc., a developer and marketer of restorative therapies processed from amniotic membrane and umbilical cord, announced the initiation of a randomized, controlled clinical trial of its proprietary product in patients with chronic wounds. [Amniox Medical, Inc. (Business Wire)] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration Australia)

Visit our events page to see a complete list of events in the cord blood community.

Postdoctoral Positions – Reprogramming and Genetic Engineering Technologies to Develop New Models of Hematopoiesis and Hematopoietic Disorders (Icahn School of Medicine)

Hematopoietic Stem Cell Scientist – Human Genetic Disorders (Editas Medicine)

Biologist or Immunologist – Hematology and Stem Cell Transplantation (University Hospital Aachen)

Postdoctoral Researcher – Hematopoietic Stem Cell Maintenance (Baylor College of Medicine)

Postdoctoral Fellow – Fetal Imprinting and Establishment of the Methylome in Cord Tissue and Placenta (University of Freiburg)

Hematology Investigator (Case Western Reserve University)

Cord Tissue Processing Technician (Cord Blood Registry)

Postdoctoral Position – Hematopoietic Stem Cell Research (UT Southwestern Medical Center at Dallas)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.